论文部分内容阅读
目的:探讨乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、癌基因HER-2、P53和Ki-67表达的临床意义.方法:收集本院156例乳腺癌临床病理学资料,采用免疫组化(S-P法)对肿瘤组织进行ER、PR、HER-2、P53和Ki-67标记。结果:156例乳腺癌组织中免疫组化检查结果显示:ER、PR、HER-2、P53和Ki-67阳性率分别为64.7%、52.7%、46.2%、48.7%、70.5%。HER-2、P53、Ki-67表达呈正相关(P<0.05),ER、PR表达与HER-2、Ki-67表达呈负相关(P<0.01)。结论:ER、PR阳性是乳腺癌预后好的指标,与肿瘤组织分级及病理分期有关(P<0.05)。HER-2阳性是预后差的指标,Ki-67与肿瘤组织分级有关(P<0.05).HER-2、Ki-67与有无淋巴结转移及肿瘤分期有关,而P53与乳腺癌病理特征无明显相关性。ER、PR、HER-2、P53、Ki-67可以协同判断淋巴结转移、评估预后。采用免疫组化(S-P法)对乳腺癌肿瘤组织进行ER、PR、HER2、P53和Ki-67标记,对乳腺癌的预后判断具有重要的临床意义。
Objective: To investigate the clinical significance of the expression of estrogen receptor (ER), progesterone receptor (PR), oncogenes HER-2, P53 and Ki-67 in breast cancer.Methods: 156 cases of breast cancer Neutrophil, ER, PR, HER-2, P53 and Ki-67 were detected by immunohistochemistry (SP method). Results: The positive rates of ER, PR, HER-2, P53 and Ki-67 in 156 cases of breast cancer were 64.7%, 52.7%, 46.2%, 48.7% and 70.5% respectively. The expression of HER-2, P53 and Ki-67 was positively correlated (P <0.05). The expression of ER and PR was negatively correlated with the expression of HER-2 and Ki-67 (P <0.01). Conclusion: The positive expression of ER and PR is a good indicator of prognosis of breast cancer, which is correlated with tumor grade and pathological stage (P <0.05). HER-2 positive is a poor prognosis index, Ki-67 and tumor grade (P <0.05) .HER-2, Ki-67 with or without lymph node metastasis and tumor staging, and P53 and breast cancer pathological features were not significantly Correlation. ER, PR, HER-2, P53 and Ki-67 can judge lymph node metastasis and evaluate the prognosis. Immunohistochemistry (S-P method) for breast cancer tissue ER, PR, HER2, P53 and Ki-67 markers, prognosis of breast cancer has important clinical significance.